Half Year 2026 Springer Nature AG & Co KgaA Earnings Call Transcript

Aug 5, 2026 / 12:00 PM GMT

Release Date Price: €18.9 (+1.50%)

Transcript

Key Points

Positve

Springer Nature AG & Co KGaA (SPGNY) delivered strong H1 2026 results with 6% underlying revenue growth and 8% adjusted operating profit growth, leading to an upgraded full-year guidance of around 6% revenue growth and at least 30 basis points of AOP margin improvement.
The research segment, which accounts for nearly 80% of group revenue, continues to be the main growth driver, with 7% underlying revenue growth, 8% AOP growth, and an almost 100% retention rate in the 2026 renewal season.
The company's leadership in open access is paying off, with article publication growth of 13% outpacing the market's estimated 8%, and submission growth of 30% continuing at similar levels seen last year.
Springer Nature AG & Co KGaA (SPGNY) is successfully leveraging AI and technology, with over 60% of submissions processed through its AI-enabled platform SNAP, and the Nature Research Assistant receiving customer satisfaction scores well above 80%.
The company delivered strong cash flow performance, with free cash flow increasing by EUR64 million to EUR268 million, and leverage reduced to 1.6 times net debt to EBITDA, well within its target range.
The divestment of consumer media businesses (Scientific American and Spectrum) increases focus on the core research segment, and the company has the ability to return excess capital via buybacks in the future.

Negative

The company faces potential regulatory headwinds from the US OMB proposals regarding federally funded research, which could impact APC and subscription revenues, although the company does not expect a negative impact on 2026 results.
Reported revenue growth was negatively impacted by currency movements, particularly the stronger euro against the US dollar and Indian rupee, as well as hyperinflation in Argentina.
The adjusted financial result was a net expense of EUR39.7 million, significantly higher than the EUR20.7 million in the prior year, due to non-recurring favorable currency translation effects in H1 2025.
The adjusted tax rate increased from 24.7% to 31.7% due to a one-off tax benefit in the prior year related to the utilization of tax losses carried forward, impacting adjusted net income.
The health segment showed weak performance with only 1% revenue and AOP growth, reflecting a difficult comparison in the Netherlands and a challenging environment for pharma marketing spend in international healthcare.
The company's AI licensing deals, such as the ARC3 partnership with Open Evidence, are not expected to have a significant short-term impact on revenues, as they are subscription-based and signed later in the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SPGG.DE - Springer Nature AG & Co KgaA
Half Year 2026 Springer Nature AG & Co KgaA Earnings Call
Aug 05, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Can you hear me?

Tell my story.

I've got this feeling so strong.

Give me person to person. Give me person to person.

You will hear music until the chairperson will open the conference.

Welcome to the Springer Nature investor conference call for the first.

Half of 2026. The conference will be recorded. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions following the presentation. Let me now turn the floor over to our host, Tom Waldron, Head of Investor Relations.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.